UroGen Pharma Ltd. — Director's Dealing 2021

Jun 9, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2021-03-25

Reporting Person: Nussbaum Ran (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-25	Ordinary Shares	M	2211	$5.00	Acquired	1433928	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-25	Stock Option (right to buy)	$5.00	M	2211	Disposed	2021-07-27	Common Stock (2211)	Indirect
2021-06-07	Stock Option (right to buy)	$17.89	A	6817	Acquired	2031-06-06	Common Stock (6817)	Indirect
2021-06-07	Stock Option (right to buy)	$17.89	A	3183	Acquired	2031-06-06	Common Stock (3183)	Indirect

Footnotes

F1: The shares underlying the stock option will vest in equal quarterly installments over a period of one year.